Lessons learned from domestic and international human papillomavirus vaccination programs: a review

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2017-09-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2017.08.109PMID 28888586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016

  2017influential reference
• Impact of Louisiana’s HPV Vaccine Awareness Policy on HPV Vaccination Among 13- to 17-Year-Old Females

  2017cited by this paper
• Global Cancer in Women: Burden and Trends

  2017cited by this paper
• Use of a 2‐Dose Schedule for Human Papillomavirus Vaccination—Updated Recommendations of the Advisory Committee on Immunization Practices

  2017cited by this paper
• Reasons for persistent suboptimal rates of HPV vaccination in the US: Shifting the focus from sexuality to education and awareness

  2017cited by this paper
• Human Papillomavirus-Associated Cancers - United States, 2008-2012.

  2016cited by this paper
• Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years Into the Danish Human Papillomavirus Vaccination Program for Girls and Women

  2016cited by this paper
• HPV Vaccine Awareness, Barriers, Intentions, and Uptake in Latina Women

  2016cited by this paper
• Interventions to Improve HPV Vaccine Uptake: A Systematic Review

  2016cited by this paper
• Impact of Virginia's School-Entry Vaccine Mandate on Human Papillomavirus Vaccination Among 13–17-Year-Old Females

  2016influential reference
• Current initiatives to protect Rhode Island adolescents through increasing HPV vaccination

  2016cited by this paper
• American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

  2016cited by this paper
• Vaccine Delays, Refusals, and Patient Dismissals: A Survey of Pediatricians

  2016cited by this paper
• Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.

  2016cited by this paper
• Rates of human papillomavirus vaccine uptake amongst girls five years after introduction of statewide mandate in Virginia.

  2016cited by this paper
• Impact of school-entry and education mandates by states on HPV vaccination coverage: Analysis of the 2009–2013 National Immunization Survey-Teen

  2016cited by this paper
• Barriers to Human Papillomavirus Vaccination Among US Adolescents: A Systematic Review of the Literature

  2015cited by this paper
• Human papillomavirus vaccine update.

  2015cited by this paper
• A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

  2015cited by this paper
• Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices

  2015cited by this paper
• Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs.

  2015cited by this paper
• Present status of human papillomavirus vaccine development and implementation.

  2015cited by this paper
• Implementation and Evaluation of a School-Based Human Papillomavirus Vaccination Program in Rural Kentucky.

  2015cited by this paper
• National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

  2015cited by this paper
• Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature.

  2014cited by this paper
• Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

  2014cited by this paper
• Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

  2014cited by this paper
• Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis

  2014cited by this paper
• Child and adolescent immunizations: selected review of recent US recommendations and literature

  2014cited by this paper
• Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program.

  2014cited by this paper
• Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.

  2014cited by this paper
• Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2014cited by this paper
• Early lessons learned from extramural school programs that offer HPV vaccine.

  2013cited by this paper
• Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008–2011

  2013cited by this paper
• Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study

  2013cited by this paper
• Population impact of HPV vaccines: summary of early evidence.

  2013influential reference
• National and State Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2012

  2013cited by this paper
• Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

  2013cited by this paper
• Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

  2013cited by this paper
• Post Approval Human Papillomavirus Vaccine Uptake Is Higher in Minorities Compared to Whites in Girls Presenting for Well-Child Care

  2013cited by this paper
• Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

  2013cited by this paper
• Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England☆

  2013cited by this paper
• Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.

  2013cited by this paper
• Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010.

  2012cited by this paper
• Introduction of human papillomavirus vaccination in Nordic countries.

  2012cited by this paper
• Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

  2012cited by this paper
• Global burden of human papillomavirus and related diseases.

  2012cited by this paper
• HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3.

  2012cited by this paper
• A review of clinical trials of human papillomavirus prophylactic vaccines.

  2012cited by this paper
• Human papillomavirus vaccine introduction--the first five years.

  2012cited by this paper
• Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

  2012cited by this paper
• Fall in human papillomavirus prevalence following a national vaccination program.

  2012cited by this paper
• Adolescent and young adult HPV vaccination in Australia: achievements and challenges.

  2011cited by this paper
• Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

  2011cited by this paper
• The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

  2011cited by this paper
• Mandatory vaccinations: The international landscape

  2011cited by this paper
• Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

  2011cited by this paper
• Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

  2011cited by this paper
• Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

  2011cited by this paper
• A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

  2011cited by this paper
• Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

  2011cited by this paper
• HPV vaccination mandates--lawmaking amid political and scientific controversy.

  2010cited by this paper
• Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

  2010cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

  2010cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• Financing the Delivery of Vaccines to Children and Adolescents: Challenges to the Current System

  2009cited by this paper
• Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women

  2009cited by this paper
• Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

  2009cited by this paper
• Human papillomavirus vaccines: WHO position paper.

  2009cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

  2007cited by this paper
• Human papillomavirus vaccine update

  2007cited by this paper
• Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update

  2007cited by this paper
• Vaccination Mandates: The Public Health Imperative and Individual Rights

  2007cited by this paper
• Public Health Strategy and the Police Powers of the State

  2005cited by this paper

• Mechanisms of Viral Oncogenesis: DNA and RNA Viruses in Human Cancer

  2025cites this paper
• Quantifying the impact of introducing HPV vaccines in 2006 on 25-29-year-old cervical cancer incidence in 2022

  2025cites this paper
• Quantifying the impact of introducing the HPV vaccine in 2006 on 25-29-year-old cervical cancer incidence in 2022

  2025cites this paper
• Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.

  2024cites this paper
• Understanding Barriers to Human Papillomavirus Vaccination among Parents of 9–10-Year-Old Adolescents: A Qualitative Analysis

  2024cites this paper
• Cancer Prevention Begins in Middle School: The Personal Advantages of HPV Immunization in Males

  2023cites this paper
• Systematic review of the use of human papillomavirus vaccine as adjuvant therapy for juvenile-onset recurrent respiratory papillomatosis.

  2022cites this paper
• The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.

  2022cites this paper
• Knowledge and Awareness of Polish Parents on Vaccination against Human Papillomavirus

  2022cites this paper
• Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.

  2021cites this paper
• Human papillomavirus vaccination: Ongoing challenges and future directions.

  2019cites this paper
• Small area estimation of human papillomavirus vaccination coverage among school-age children in Alabama counties.

  2019cites this paper
• Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries

  2019cites this paper
• School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas

  2019influential citation
• HPV vaccination.

  2018cites this paper
• The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama.

  2018cites this paper